Label Changes for:
Desferal (deferoxamine mesylate) injection
Changes have been made to the WARNINGS and ADVERSE REACTIONS sections of the safety label.
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – September 2010
- Increases in serum creatinine (possibly dose-related), acute renal failure and renal tubular
disorders, associated with the administration of deferoxamine, have been reported in
Hepatic: hepatic dysfunction
Urogenital: acute renal failure